tocilizumab
Actemra (tocilizumab) is an interleukin-6 receptor antagonist from Roche for rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, severe CAR T cell-induced cytokine release syndrome, and hospitalized adults with severe COVID-19. It blocks IL-6 signalling that drives inflammatory disease.
This page is based on FDA prescribing information and the EMA medicine record for tocilizumab, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In inflammatory diseases the immune system keeps shouting one message over and over: IL-6. That constant signal keeps joints swollen, arteries inflamed, or the whole body in overdrive. Tocilizumab is an earmuff for the message, covering the IL-6 receptor so cells can no longer hear the signal, and the inflammation winds down.
In simple terms
Tocilizumab is a recombinant humanized antibody that binds the interleukin-6 receptor, both the soluble form floating in the blood and the form attached to cells. By doing so it blocks IL-6, a key inflammatory signal, from engaging its receptor and stops IL-6-mediated signalling. Since IL-6 is overproduced in rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions, blocking it reduces joint damage, inflammation, and the dangerous cytokine surge that can follow CAR T-cell therapy.
In depth
Tocilizumab is a recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. It targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor and preventing IL-6-mediated signalling. IL-6 is a pro-inflammatory cytokine that plays an important role in the regulation of the immune response and is overproduced in autoimmune disorders, certain types of cancer, and various other inflammatory conditions.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
In inflammatory diseases the immune system keeps shouting one message over and over: IL-6.
- IL-6 is a pro-inflammatory cytokine that is overproduced in autoimmune and inflammatory disorders.
- Tocilizumab binds the interleukin-6 receptor, both the soluble form floating in the blood and the form attached to cells.
- Tocilizumab is an earmuff for the message, covering the IL-6 receptor so cells can no longer hear the signal, and the inflammation winds down.
- Since IL-6 is overproduced in rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions, blocking it reduces joint damage, inflammation, and the dangerous cytokine surge that can follow CAR T-cell therapy.
Target: Interleukin-6 receptor (IL-6R)
The receptor for IL-6, a pro-inflammatory cytokine overproduced in autoimmune and inflammatory disorders; blocking the receptor silences IL-6 signalling and calms the inflammatory response.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- For the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)
- For the treatment of giant cell arteritis in adult patients
- For the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis
- For the treatment of patients 2 years of age and older with active systemic juvenile idiopathic arthritis
- For the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome
- For the treatment of hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
Approved uses in European Union
EMA- In combination with methotrexate, for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, and for moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor antagonists, with monotherapy possible in case of methotrexate intolerance or where continued methotrexate treatment is inappropriate
- For the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids, as monotherapy or in combination with methotrexate
- In combination with methotrexate, for the treatment of juvenile idiopathic polyarthritis in patients 2 years of age and older who have responded inadequately to previous therapy with methotrexate, with monotherapy possible in case of methotrexate intolerance or where continued methotrexate treatment is inappropriate
Official sources
The statements on this page trace back to these records.
- RoActemra (tocilizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: tocilizumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: tocilizumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.